BIOSENIC SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0143 EUR | -2.72% |
|
+5.93% | -76.63% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Capitalization 1 | 9.485 | 3.156 | 3.156 |
| Enterprise Value (EV) 1 | 9.485 | 21.96 | 32.46 |
| P/E ratio | -3.06 x | -0.29 x | -0.16 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | -4.39 x | -2.87 x |
| EV / FCF | - | -4.31 x | -3.15 x |
| FCF Yield | - | -23.2% | -31.7% |
| Price to Book | - | -0.49 x | -0.15 x |
| Nbr of stocks (in thousands) | 154,978 | 214,699 | 214,699 |
| Reference price 2 | 0.0612 | 0.0147 | 0.0147 |
| Announcement Date | 4/24/23 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net sales 1 | - | - | - |
| EBITDA 1 | - | -5 | -11.3 |
| EBIT 1 | -2.318 | -5.2 | -11.5 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) | -3.049 | - | - |
| Net income 1 | -2.041 | -5.8 | -11.2 |
| Net margin | - | - | - |
| EPS 2 | -0.0200 | -0.0500 | -0.0900 |
| Free Cash Flow 1 | - | -5.1 | -10.3 |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 4/24/23 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Debt 1 | - | 18.8 | 29.3 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | - | -3.76 x | -2.593 x |
| Free Cash Flow 1 | - | -5.1 | -10.3 |
| ROE (net income / shareholders' equity) | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share 2 | - | -0.0300 | -0.1000 |
| Cash Flow per Share 2 | - | -0.0400 | -0.0900 |
| Capex 1 | - | 0.2 | 0.2 |
| Capex / Sales | - | - | - |
| Announcement Date | 4/24/23 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.0147
EUR
Average target price
0.1
EUR
Spread / Average Target
+580.27%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -76.63% | 3.43M | |
| +33.11% | 709B | |
| +30.77% | 595B | |
| -2.14% | 367B | |
| +20.30% | 334B | |
| +5.27% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.11% | 171B |
- Stock Market
- Equities
- BIOS Stock
- Financials BioSenic SA